VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
VERU INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.31+0.01 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $53.25M
- P/E (TTM)
- –
- Dividend yield
- –
VERU INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | – | $5.22M | $1.29M | – | – | – |
| South Africa | – | – | – | – | – | – | – | $2.96M | $951.00K | – | – | – |
| Zimbabwe | – | – | – | – | – | – | – | $2.16M | $2.23M | – | – | – |
| Other Countries [Member] | – | – | – | – | – | – | – | $4.52M | $7.76M | – | – | – |
| Mozambique | – | – | – | – | – | – | – | – | $1.43M | – | – | – |
| Kenya | – | – | – | – | – | – | – | $1.01M | – | – | – | – |
| FC2 Segment [Member] | – | – | – | – | $60.40M | $40.56M | $30.92M | $15.85M | – | – | – | – |
| PREBOOST Segment [Member] | – | – | – | – | $862.83K | $2.04M | $884.02K | $11.90K | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate [Member] | – | – | – | – | $2.35B | -$24.37B | -$9.16B | -$12.01M | -$8.39M | -$6.82M | – |
| R&D [Member] | – | – | – | – | – | – | – | – | -$3.24M | -$89.00K | – |
| Commercial [Member] | – | – | – | – | – | – | $15.86M | $1.94M | $3.14M | – | – |
| Research and Development Expense [Member] | – | – | – | – | – | – | -$13.69M | -$10.81M | -$3.24M | – | – |
| Research and Development [Member] | – | – | – | – | -$33.39B | -$16.87B | -$13.97B | – | – | – | – |
| Sexual Health Business [Member] | – | – | – | – | $44.02B | $26.50B | $16.70B | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FC2, U.S. Prescription Channel [Member] | – | – | $5.82M | $30.22M | $46.47M | – | – | – | – | – | – | – |
| Other [Member] | – | – | $13.01K | $2.42K | $862.83K | – | – | – | – | – | – | – |
| FC2, Global Public Health Sector [Member] | – | – | $10.46M | $9.13M | $13.93M | – | – | – | – | – | – | – |
| FC2 [Member] | – | – | $16.28M | $39.35M | $60.40M | – | – | – | – | – | – | – |
| FC2 Female Condom [Member] | – | $16.89M | $16.28M | – | – | – | – | – | – | – | – | – |
| Product and Service, Other [Member] | – | $0 | $13.01K | – | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | $5.35M | $8.37M | $31.43M | $48.94M | $30.34M | $17.26M | $5.22M | $1.29M | $2.46M | – | – |
| Other Countries [Member] | – | – | $5.99M | $7.92M | $12.32M | $12.25M | $14.54M | $5.52M | $6.02M | $9.23M | – | – |
| Brazil | – | $2.76M | – | – | – | – | – | – | – | $6.01M | – | – |
| South Africa | – | $1.90M | $1.94M | – | – | – | – | $2.96M | $951.00K | $1.12M | – | – |
| Zimbabwe | – | – | – | – | – | – | – | $2.16M | $2.23M | $3.31M | – | – |
| Nigeria | – | – | – | – | – | – | – | – | $846.00K | – | – | – |
| Cameroon | – | – | – | – | – | – | – | – | $891.00K | – | – | – |
| Mozambique | – | $2.17M | – | – | – | – | – | – | $1.43M | – | – | – |
| Other Geographical Areas [Member] | – | $4.70M | $5.99M | – | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of VERU's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.